Last close As at 05/08/2026
GBP18.88
▲ 108.00 (6.07%)
Market capitalisation
GBP572m
Avon Protection has seen a further underpinning of its FY21 revenue expectations following the award of a dual-source framework supply contract from the US Army for the supply of next generation body armour plates as part of its Soldier Protection System. It is the first major award since the acquisition of the new Helmets & Armor operation in January 2020. The award was anticipated in guidance and there is no change to our expectations but it clearly adds to sales cover for our FY21 estimates. Avon is trading on a FY21e P/E of 23.8x, reflecting its continuing positive momentum.
Written by
Avon Rubber |
Multi-year body armour contract award |
US Army contract |
Aerospace & defence |
2 March 2020 |
Share price performance
Business description
Analyst
Avon Rubber is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||
Avon Protection has seen a further underpinning of its FY21 revenue expectations following the award of a dual-source framework supply contract from the US Army for the supply of next generation body armour plates as part of its Soldier Protection System. It is the first major award since the acquisition of the new Helmets & Armor operation in January 2020. The award was anticipated in guidance and there is no change to our expectations but it clearly adds to sales cover for our FY21 estimates. Avon is trading on a FY21e P/E of 23.8x, reflecting its continuing positive momentum.
Year end |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
09/18 |
165.5 |
27.2 |
76.6 |
16.0 |
35.6 |
0.6 |
09/19 |
179.3 |
31.4 |
90.9 |
20.8 |
30.0 |
0.8 |
09/20e |
233.0 |
35.4 |
93.1 |
27.1 |
29.3 |
1.0 |
09/21e |
256.4 |
43.6 |
114.7 |
35.2 |
23.8 |
1.3 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
The new contract is dual source and runs for four years with a maximum value of $265m. The contract is for the supply to the US Army of next generation Virtual Torso Protection X-Side Ballistic Insert (VTP XSBI) body armour plates. Each order under the framework will be awarded on a competitive basis Deliveries are expected to commence in FY21 following product approvals. It adds to a similar existing $704m four-year contract split between three suppliers for enhanced small arms protection systems. Experience on that programme suggests that supply contract awards for body armour under the two framework contracts should be fairly evenly split, which could contribute c $30m of revenue per annum for Avon Protection from FY21.
|
|
Research: Healthcare
Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26% and EBITDA margin expansion of 620bp to 16.0%. Total revenues of €382.5m were driven by its low molecular weight heparin (LMWH) franchise (Becat and Hibor) and toll manufacturing business. Becat (enoxaparin biosimilar) and flagship drug Hibor (bemiparin) reported combined sales of €177.6m (+46%). ROVI has consolidated its toll manufacturing units into a single entity; this division grew 20% in 2019 (€65.6m). Management has guided to mid-single digit growth in total operating revenues for 2020, which seems conservative. The MAA for DORIA has now been filed with the EMA (January 2020) and the NDA filing with the FDA is expected in H220. We value ROVI at €1.49bn.